Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Renalytix plcRNLX · Entity 7446 | Chief Business Officer | November 20, 2023 | November 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Renalytix plc
Report date November 20, 2023 · Filed November 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-11-19 | Direct | 300,000 |
Reported balance
After 2023-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-20 · Grant · Acquired 300,000 · Balance 300,000 F1: The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243). F2: One third (1/3rd) of the shares subject to the option award shall vest on September 1, 2024, and one eighth (1/8th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).
F2: One third (1/3rd) of the shares subject to the option award shall vest on September 1, 2024, and one eighth (1/8th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2023 Filed Nov 22, 2023 21:27 UTC | Renalytix plc RNLX · Entity 7446 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-23-056474 · doc4.xml · derivative · entry 1 Doran Howard JR · CIK 0001415965 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Ordinary Shares · 300,000 shares Expires 2033-11-19 F1 · derivative.exercise_price: The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243). F2 · derivative.exercise_date: One third (1/3rd) of the shares subject to the option award shall vest on September 1, 2024, and one eighth (1/8th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.